Comparison of Study Designs for Primary Phase III Trials for Omalizumab Versus Dupilumab for Patients With Chronic Spontaneous Urticaria. (2023). SKIN The Journal of Cutaneous Medicine, 7(6), s299. https://doi.org/10.25251/skin.7.supp.299